Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for the treatment of glioblastoma

a glioblastoma and antibody technology, applied in the field of disease and pathological conditions with antivegf antibodies, can solve the problems of high unmet medical needs and limited treatment options of diseases, and achieve the effect of prolonging the patient's median overall survival tim

Active Publication Date: 2015-03-05
GENENTECH INC
View PDF2 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a combination of an anti-VEGF antibody and chemotherapy for treating glioblastoma. This treatment can prolong the patient's survival compared to chemotherapy alone. The combination can be used in patients who have not previously received anti-cancer therapy and may be more effective in treating proneural glioblastoma and newly diagnosed glioblastoma. The anti-VEGF antibody used can be bevacizumab.

Problems solved by technology

Although some progress has been made in the treatment of glioblastoma, this disease presents a highly unmet medical need with limited treatment options.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for the treatment of glioblastoma
  • Combination therapy for the treatment of glioblastoma
  • Combination therapy for the treatment of glioblastoma

Examples

Experimental program
Comparison scheme
Effect test

example 1

AvaGlio Study

[0146]The AvaGlio trial evaluated the efficacy and safety of bevacizumab in combination temozolomide and radiotherapy for newly diagnosed glioblastoma. This study was designed as a prospective, randomized, double blind, placebo controlled Phase III evaluation of bevacizumab plus chemotherapy versus chemotherapy alone. To be eligible, patients must have had newly diagnosed glioblastoma with a tissue diagnosis that has been established following either a surgical resection or biopsy. By adding bevacizumab to chemotherapy and radiotherapy, the AvaGlio trial aimed to improve overall survival (OS) and progression-free survival (PFS) for this group of patients who had limited therapeutic options and faced a particularly poor prognosis. The primary objective was to compare OS and PFS of patients randomized to temozolomide (TMZ) and radiotherapy only or to temozolomide and radiotherapy plus bevacizumab.

Overview of AvaGlio Study

[0147]This trial consisted of three phases (Concurr...

example 2

Categorizing FFPE-Fixed Samples Using Nanostring Gene Expression Data

[0154]Stratification of clinical samples into gene expression subtypes is complicated by the fact that standard sample preparation, e.g., fixation using formalin-fixed, paraffin-embedded (FFPE) techniques, reduces the quality and amount of RNA available for analysis using standard methods, e.g. microarrays. Recently, single-molecule analysis technologies, e.g. the Nanostring nCounter (Geiss et al. Biotechnol. 26(3): 317-325, 2008), have become available to assay gene expression in FFPE-fixed material.

[0155]To assign patient-derived samples into gene expression subtypes originally defined from fresh-frozen samples analyzed on microarrays, we applied a four-step approach. Specifically, we:[0156]1. Re-normalized published microarray data for 98 samples classified by Lai et al and calculated the gene expression centroids for the 35 classifier genes (reference data).[0157]2. Applied the centroids to classify a new set o...

example 3

Nanostring-Based Classification of Samples from the AvaGlio Trial

[0171]Next, we classified the 349 samples from the AvaGlio trial for which biomarkers could be evaluated into the gene expression subtypes defined by Phillips (Cancer Cell. 9(3): 157-173, 2006). Selected baseline characteristics of the 349 biomarker evaluable patients within each treatment arm are shown in Table 6.

TABLE 6Selected baseline characteristics of biomarker evaluable patientsBiomarker Evaluable PatientsRT / TMZ / PLBRT / TMZ / BEVPatients, %(n = 178)(n = 171)Median age,58 (21-79)59 (28-84)years (range)GenderMale6460Female3640WHO PS050471-24749RPA class - CRFIII1214IV6359V2224MGMT statusMethylated2623Non-methylated4956Surgical statusBiopsy66Partial resection5244Complete resection3946KPS50-80323290-1006564MMSE score2222≧277573CorticosteroidsOn4740Off4954

Samples were analyzed with the same Nanostring probe set used to derive the subtype-specific centroids and expression scores for the same genes were obtained using the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Timeaaaaaaaaaa
Login to View More

Abstract

This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.

Description

FIELD OF THE INVENTION[0001]This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with glioblastoma using an anti-VEGF antibody, in combination with one or more additional anti-tumor therapeutic agents.BACKGROUND OF THE INVENTION[0002]Gliomas account for 81% of all malignant brain and CNS tumors. Glioblastoma (glioblastoma multiforme (GBM); World Health Organization (WHO) grade IV astrocytoma), in particular, accounts for 60% to 70% of malignant gliomas and remains the most aggressive subtype of glioma. It occurs mostly in adults (median age at diagnosis: 64 years) and its incidence is estimated to be 3.05 / 100,000 in the United States. With 1- and 5-year overall survival of 29% and 3%, respectively, the prognosis of glioblastoma remains particularly poor (Central Brain Tumor Registry of the United States (2005) (CBTRUS; http:...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K31/495
CPCA61K39/3955A61K2039/505A61K31/495A61K39/39541C07K16/22A61K45/06A61P35/00A61K2300/00A61K39/00
Inventor BAIS, CARLOSBOURGON, RICHARDPHILLIPS, HEIDISANDMANN, THOMAS
Owner GENENTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com